What is Spyre Therapeutics, Inc.'s free cash flow yield?

Spyre Therapeutics, Inc. (SYRE) reported free cash flow yield of -11.3% in Q4 2024.

What is the long-term trend for Spyre Therapeutics, Inc.'s free cash flow yield?

Over 3 years (2020 to 2024), Spyre Therapeutics, Inc.'s free cash flow yield has grown at a -16.0% compound annual growth rate (CAGR), from -19.1% to -11.3%.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

Spyre Therapeutics, Inc. SYRE Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers SquibbBMY

9.6%-0.9pp

Eli LillyLLY

1.4%+0.9pp

PfizerPFE

7.8%+4.6pp

Johnson & JohnsonJNJ

3%-2.1pp

Merck & Co.MRK

4.7%-2.8pp

AbbVieABBV

5.2%+1.0pp

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Calculated from Spyre Therapeutics, Inc.’s reported figures.

free cash flow/market cap=-11.3%

Based on trailing twelve months.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s free cash flow yield?: Spyre Therapeutics, Inc. (SYRE) reported free cash flow yield of -11.3% in Q4 2024.
What is the long-term trend for Spyre Therapeutics, Inc.'s free cash flow yield?: Over 3 years (2020 to 2024), Spyre Therapeutics, Inc.'s free cash flow yield has grown at a -16.0% compound annual growth rate (CAGR), from -19.1% to -11.3%.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.